American heart journal
American heart journal
Audio Summaries
Every issue of American heart journal moves the field forward, but reading every paper cover-to-cover isn't realistic. OSLR turns each article into a 3-minute audio summary so you can stay current while you commute, round, or work out.
Recent summaries
The latest articles summarized from American heart journal.
Culprit vessel TIMI 0-1 flow identifies a high-risk subgroup of NSTEMI patients with multivessel disease: a post-hoc analysis of the SLIM randomized clinical trial.
Nov 20, 2026
This post-hoc analysis of the SLIM randomized trial asks whether culprit-vessel TIMI 0-1 flow, a surrogate for occlusive myocardial infarction, identifies a high-risk subgroup among NSTEMI patients with multivessel disease. In 474 patients, TIMI 0-1 flow was not detectable on admission ECG interpretation, was more common in younger male patients with a circumflex culprit, and was independently associated with higher 1-year MACE after adjustment (aHR 2.09, p=0.026), though unadjusted rates did not differ significantly (p=0.061).
Rationale and Design of the MICRA-HYBRID Trial: Multivessel Minimally Invasive Coronary Bypass Grafting as HYBRID Revascularization Versus Conventional Off-pump Coronary Artery Bypass Grafting.
Nov 19, 2026
The MICRA-HYBRID trial asks whether multivessel hybrid coronary revascularization, combining minimally invasive LAD and circumflex grafting with percutaneous RCA intervention, is superior to conventional off-pump CABG in patients with three-vessel coronary artery disease. In this dual-center randomized trial of 250 patients, the primary endpoint is a 30-day "textbook outcome," a composite of freedom from mortality, major surgical and cardiac complications, and prolonged hospitalization. Secondary endpoints include quality of life, pulmonary recovery, short-term costs, and 5-year major adverse cardiac and cerebrovascular events.
Design and rationale of MIRACLE, a prospective multicenter cohort study with integrated biobanking in cardiogenic shock.
Nov 18, 2026
MIRACLE is a prospective, multicenter German cohort that enrolls adults with cardiogenic shock or preshock of any cause (plus large anterior STEMI controls without shock), serially restaging SCAI stages and collecting repeated biobank samples through day 5 and 6-month follow-up. The study aims to characterize multimodal phenotypes and risk-stratify patients across shock etiologies, with 30-day all-cause mortality as the primary endpoint. As of September 2026, 449 shock/preshock patients had been enrolled, with 30-day mortality of 15% in SCAI B and 63% in SCAI E (35% overall).
Left Atrial Appendage Closure Versus DOAC Therapy in Atrial Fibrillation: A Phenotype-Centered Systematic Review and Meta-analysis of Randomized Trials.
Nov 18, 2026
This meta-analysis of five randomized trials (n = 6,239) asked whether left atrial appendage closure (LAAC) is a viable alternative to direct oral anticoagulants (DOACs) for patients with non-valvular high-risk atrial fibrillation. LAAC showed no significant difference in mortality or stroke compared with DOACs, but it was associated with less nonprocedural clinically relevant bleeding and more systemic thromboembolism, pericardial effusion, and serious adverse events. The authors conclude that LAAC should be selected for specific patient phenotypes rather than routinely substituted for anticoagulation.
Drug Development in Pediatric Heart Failure: Current Landscape and Future Directions.
Nov 18, 2026
This review examines the current landscape of pediatric heart failure drug development, where most treatments are adult drugs used off-label and regulatory guidance is limited. The authors ask how drug development can shift toward a mechanism-of-action-driven approach and a new high-level phenotype classification, given the diverse pathophysiology of pediatric HF. They propose that pharmacokinetic extrapolation, bridging biomarkers, adaptive trial designs, and harmonized regulatory frameworks offer promising paths forward in the absence of validated surrogate endpoints.
Selective serotonin reuptake inhibitors And Depression in Atrial Fibrillation: Design of the SAD-AF Randomized Controlled Trial.
Nov 18, 2026
This randomized, single-blind trial asks whether escitalopram, an SSRI antidepressant, improves quality of life, reduces atrial fibrillation (AF) burden, and lowers AF-related hospital presentations in patients with paroxysmal or persistent AF and depressive symptoms (PHQ-9 ≥8), compared with placebo added to standard care. The primary outcome is the AFEQT quality-of-life score in 154 planned participants, with AF burden measured via wearable or implanted-device monitoring and autonomic function assessed through blood pressure and heart rate variability.
Association between Physical Function and Incidence of Atrial Fibrillation: The Atherosclerosis Risk in Communities (ARIC) Study.
Nov 17, 2026
Using data from 4,803 older adults in the ARIC Study, this study asked whether poorer physical function is associated with a higher risk of incident atrial fibrillation (AF). Over a median of 9.2 years, better SPPB scores and greater grip strength were linked to lower AF risk, while slower 4-meter walk times were linked to higher risk, with the SPPB showing the strongest association and the chair stand component driving that relationship. The findings suggest that physical function, a modifiable factor, may be a potential target for AF prevention in aging populations.
Antithrombotic therapy in patients with atrial fibrillation and acute coronary syndrome treated with percutaneous coronary intervention. -insights from the SWEDEHEART registry.
Nov 17, 2026
This SWEDEHEART registry study examined how antithrombotic prescribing changed over 2010-2022 in patients with atrial fibrillation and acute coronary syndrome undergoing PCI, and whether treatment strategies were linked to outcomes. Among 15,358 patients, oral anticoagulation use rose from 27% in 2010 to 82% in 2021, and both vitamin K antagonist-based and DOAC-based strategies were associated with lower rates of MACE and NACE compared with platelet inhibition alone, with no significant difference between the two anticoagulant strategies. Because the analysis is observational, these associations may be affected by residual confounding.
Inflammation and the Association of Early-stage Cardiovascular-Kidney-Metabolic Syndrome with Incident Cardiovascular Disease and All-cause Mortality: Findings from the CARDIA and MESA Cohorts.
Nov 15, 2026
This study used data from 9,894 CVD-free adults in the CARDIA and MESA cohorts to test whether inflammation, measured by IL-6 (primary) and hsCRP (secondary), modifies the link between early-stage cardiovascular-kidney-metabolic (CKM) syndrome (stages 2-3 vs 0-1) and incident atherosclerotic CVD, heart failure, and all-cause mortality. Higher IL-6 was independently associated with greater risk of all three outcomes, and it showed additive (but not multiplicative) interaction with CKM stage for atherosclerotic CVD, with hsCRP showing no consistent modification. Overall, the findings suggest that elevated IL-6 may compound cardiovascular risk among adults with early-stage CKM syndrome, though effect modification was limited to one outcome and one measure of interaction.
Rationale and Design of The Congenital Cardiac Research Collaborative Pulmonary Vein Stenosis Registry.
Nov 14, 2026
This paper describes the design of the Congenital Cardiac Research Collaborative Pulmonary Vein Stenosis Registry, a multicenter, ambispective longitudinal cohort of pediatric patients with multi-vessel pulmonary vein stenosis treated at 19 U.S. centers beginning in 2022. The registry collects data from initial evaluation and intervention through ongoing follow-up, including reinterventions, medical therapy, resource use, and patient- and vein-level outcomes. The authors aim to address knowledge gaps in measuring PVS severity, identifying which treatments and comorbidities influence outcomes, and guiding quality improvement and future research.
